Abstract：
OBJECTIVE: This study investigated the impact of an advanced analytics software solution in the operating room (OR) on tracking and evaluating controlled substance discrepancies. The authors hypothesized that the software would increase identification of these discrepancies and improve the efficiency of the preexisting manual process.
METHODS: In this evaluation comparing data from before to after implementation of the software, data were collected using the preexisting manual process for 50 days before implementation, followed by a 25-day period for acclimation to the new software, and ending with a 49-day postimplementation review period. Data collected included the total number of medication discrepancies, time required for discrepancy review and reconciliation by an OR analyst, types of discrepancies, and number of discrepancies leading to provider audits.
RESULTS: Before implementation of the analytics software, there were 7,635 OR cases with a total of 674 charting discrepancies (8.83 discrepancies per 100 total OR cases) discovered across 439 OR cases. After implementation, there were 7,454 OR cases with a total of 930 charting discrepancies (12.48 discrepancies per 100 total OR cases; P < 0.0001) discovered across 680 OR cases. While discrepancies increased by 38%, the median review time for the OR analyst per case decreased (P < 0.0001) and the percentage of incidents resolved by the OR analyst increased by 14% while the number of cases requiring additional documentation by the provider decreased by 10%.
CONCLUSIONS: Implementation of advanced analytics software in the OR significantly increased the number of controlled substance charting discrepancies identified compared to the preimplementation review process while increasing the efficiency of the OR analyst.
METHODS: In this evaluation comparing data from before to after implementation of the software, data were collected using the preexisting manual process for 50 days before implementation, followed by a 25-day period for acclimation to the new software, and ending with a 49-day postimplementation review period. Data collected included the total number of medication discrepancies, time required for discrepancy review and reconciliation by an OR analyst, types of discrepancies, and number of discrepancies leading to provider audits.
RESULTS: Before implementation of the analytics software, there were 7,635 OR cases with a total of 674 charting discrepancies (8.83 discrepancies per 100 total OR cases) discovered across 439 OR cases. After implementation, there were 7,454 OR cases with a total of 930 charting discrepancies (12.48 discrepancies per 100 total OR cases; P < 0.0001) discovered across 680 OR cases. While discrepancies increased by 38%, the median review time for the OR analyst per case decreased (P < 0.0001) and the percentage of incidents resolved by the OR analyst increased by 14% while the number of cases requiring additional documentation by the provider decreased by 10%.
CONCLUSIONS: Implementation of advanced analytics software in the OR significantly increased the number of controlled substance charting discrepancies identified compared to the preimplementation review process while increasing the efficiency of the OR analyst.
摘要：
结论：为了加快文章的发表，AJHP在接受后尽快在线发布手稿。接受的手稿经过同行评审和复制编辑，但在技术格式化和作者打样之前在线发布。这些手稿不是记录的最终版本，将在以后替换为最终文章（按照AJHP样式格式化并由作者证明）。
目的：本研究调查了手术室（OR）高级分析软件解决方案对跟踪和评估受控物质差异的影响。作者假设该软件将增加对这些差异的识别，并提高现有手动过程的效率。
方法：在此评估中，比较软件实施前后的数据，数据在实施前使用现有的手动流程收集50天，接下来是25天的时间来适应新软件，并以49天的实施后审查期结束。收集的数据包括药物差异的总数，OR分析师进行差异审查和对账所需的时间，差异类型，以及导致提供商审计的差异数量。
结果：在实施分析软件之前，共有7,635例OR病例,在439例OR病例中发现了674个图表差异(每100例OR病例中有8.83个差异).实施后，在680例OR病例中发现了7,454例OR病例，共有930个图表差异（每100例OR病例中有12.48个差异；P<0.0001）。虽然差异增加了38%，OR分析员每个病例的中位审查时间减少(P<0.0001),OR分析员解决的事件百分比增加了14%,而需要提供者提供额外文件的病例数减少了10%.
结论：与实施前审查流程相比，在手术室中实施高级分析软件显著增加了确定的受控物质图表差异的数量，同时提高了手术室分析师的效率。
目的：本研究调查了手术室（OR）高级分析软件解决方案对跟踪和评估受控物质差异的影响。作者假设该软件将增加对这些差异的识别，并提高现有手动过程的效率。
方法：在此评估中，比较软件实施前后的数据，数据在实施前使用现有的手动流程收集50天，接下来是25天的时间来适应新软件，并以49天的实施后审查期结束。收集的数据包括药物差异的总数，OR分析师进行差异审查和对账所需的时间，差异类型，以及导致提供商审计的差异数量。
结果：在实施分析软件之前，共有7,635例OR病例,在439例OR病例中发现了674个图表差异(每100例OR病例中有8.83个差异).实施后，在680例OR病例中发现了7,454例OR病例，共有930个图表差异（每100例OR病例中有12.48个差异；P<0.0001）。虽然差异增加了38%，OR分析员每个病例的中位审查时间减少(P<0.0001),OR分析员解决的事件百分比增加了14%,而需要提供者提供额外文件的病例数减少了10%.
结论：与实施前审查流程相比，在手术室中实施高级分析软件显著增加了确定的受控物质图表差异的数量，同时提高了手术室分析师的效率。
